Login / Signup

Severe hyperglycemia following transition from octreotide to lanreotide in a patient with enterocutaneous fistula receiving parenteral nutrition.

Abbie N RosenJulia R BalazhAndrew J Franck
Published in: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2021)
Somatostatin analogues, suchas octreotide and lanreotide, are commonly used in the management of enterocutaneous fistula. We report a case of severe and prolonged hyperglycemia that occurred in a patient after receiving a one-time dose of lanreotide, who had previously been stable on octreotide and did not have a history of diabetes mellitus. Management of the patient's hyperglycemia while receiving parenteral nutrition is described.
Keyphrases
  • case report
  • neuroendocrine tumors
  • early onset
  • metabolic syndrome
  • oxidative stress
  • glycemic control